Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) – Pipeline Review, H2 2016’, provides in depth analysis on Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted pipeline therapeutics.

The report provides comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)

The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects

The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Cancer Research Technology Ltd

Cantex Pharmaceuticals Inc

Genentech Inc

Momenta Pharmaceuticals Inc

Noxxon Pharma AG

TikoMed AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) Overview 7

Therapeutics Development 8

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Products under Development by Stage of Development 8

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Products under Development by Therapy Area 9

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Products under Development by Indication 10

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Products under Development by Companies 14

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Products under Development by Universities/Institutes 16

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development 25

Cancer Research Technology Ltd 25

Cantex Pharmaceuticals Inc 26

Genentech Inc 27

Momenta Pharmaceuticals Inc 28

Noxxon Pharma AG 29

TikoMed AB 30

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles 31

114-3H1 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CX-01 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Genistein - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

IBsolvMIR - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

MAb-30D8 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

necuparanib - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

olaptesed pegol - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Projects 48

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products 51

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Featured News & Press Releases 52

Oct 10, 2016: NOXXON Pharma Demonstrates Synergies between NOX-A12 and Therapies Working Through T Cells or NK Cells 52

Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis 52

Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 53

May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 54

Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia 55

Jan 20, 2016: NOXXON Pharma Hosts Key Opinion Leader Symposium 55

Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 56

Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 56

Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 56

Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01 57

May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 58

May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting 59

Dec 05, 2014: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference 59

Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer 61

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer 61

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by Cancer Research Technology Ltd, H2 2016 25

Pipeline by Cantex Pharmaceuticals Inc, H2 2016 26

Pipeline by Genentech Inc, H2 2016 27

Pipeline by Momenta Pharmaceuticals Inc, H2 2016 28

Pipeline by Noxxon Pharma AG, H2 2016 29

Pipeline by TikoMed AB, H2 2016 30

Dormant Projects, H2 2016 48

Dormant Projects (Contd..1), H2 2016 49

Dormant Projects (Contd..2), H2 2016 50

Discontinued Products, H2 2016 51

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports